FDA Non-Animal Testing Policy Expands Nonclinical Options

The U.S. Food and Drug Administration (FDA) non-animal testing policy is being embedded in the language of drug regulation.

The FDA’s September 2026 rulemaking updates terminology across key drug and biologics regulations while a new database shows where New Approach Methodologies (NAMs) have already appeared in FDA-reviewed applications.

The significance is therefore broader than a wording change. It signals a regulatory framework increasingly organised around the quality and relevance of nonclinical evidence, rather than assuming that animal studies are the default route for generating it.

Image

From Animal Testing Language to Nonclinical Evidence

On 22 September 2026, the FDA published two linked regulatory documents addressing nonclinical testing terminology.

The first is a Direct Final Rule and the second is a companion Proposed Rule that provides an alternative route if the Direct Final Rule receives significant adverse comments.

Together, they update terminology in parts 312, 314, 315, 361 and 601 of Title 21 of the Code of Federal Regulations.

The Direct Final Rule replaces references such as “animal test” and “animal study” with “nonclinical test” and “nonclinical study”. It also introduces definitions for those terms and makes related terminology changes, including replacing certain references to “preclinical” and “in vitro” with “nonclinical”. 

The regulatory change follows amendments made through the Food and Drug Omnibus Reform Act of 2022 (FDORA).

FDORA established a statutory definition of a nonclinical test that can encompass in vitro, in silico, in chemico and nonhuman in vivo approaches. Examples include cell-based assays, organ chips, microphysiological systems, computer modelling and bioprinting, alongside animal tests. 

That is vital. The FDA is not removing animal studies from the regulatory toolkit. The amended framework is designed to recognise a wider range of scientifically valid approaches for generating nonclinical evidence.

The agency states that the rule does not create new industry requirements, change evidentiary standards, or prohibit animal testing. Instead, it removes regulatory language that could imply that animal testing is the only scientific route for assessing safety before human studies. 

That creates a clearer regulatory vocabulary around an already changing scientific landscape.

Why terminology matters to development teams

Regulatory terminology influences how companies interpret requirements when designing development programmes.

If a regulation refers specifically to an “animal study”, sponsors may reasonably interpret that language as prescribing a particular testing modality. A broader reference to a “nonclinical study” creates more room to consider alternative evidence where the science supports it.

The FDA’s proposed definition is deliberately broad. It encompasses methods conducted outside animals as well as nonhuman in vivo testing.

That means the regulatory category becomes method-neutral, while the scientific question and evidentiary value remain central.

This does not mean that every NAM will automatically satisfy FDA requirements.

The agency’s March 2026 draft guidance on NAMs sets out general considerations for developers using these approaches in drug development.

The FDA’s NAM guidance emphasises scientific principles around study design, reporting and the use of NAMs in regulatory submissions. 

The practical implication is important for regulatory strategy.

Sponsors still need to establish that a particular methodology is appropriate for the product, endpoint and regulatory question. The terminology change does not turn an emerging technology into an automatically acceptable substitute.

The Regulatory Route Is Part of the Story

The choice to issue a Direct Final Rule alongside a companion Proposed Rule is one of the more significant procedural aspects of the announcement.

Ordinarily, a substantive FDA regulation follows a familiar sequence of proposed rulemaking, public comments, agency review, and finalisation. 

In this instance, the FDA has used direct final rulemaking, stating that it considers these amendments noncontroversial and does not expect significant adverse comments. 

The companion proposal provides a fallback mechanism.

The public comment period for both documents closes on 7 December 2026.

If the FDA receives timely significant adverse comments, it intends to withdraw the Direct Final Rule and proceed through the conventional notice-and-comment route using the companion Proposed Rule. If that does not occur, the FDA intends to confirm the effective date within 30 days after the comment period closes. 

The Direct Final Rule currently specifies an effective date of 4 February 2027, subject to that process. 

This mechanism provides an important signal about how the FDA characterises the change.

The agency is not presenting the terminology amendments as a new safety standard or a new burden on sponsors. It describes them as an alignment of existing regulations with statutory amendments and the expanding role of scientifically valid nonclinical methodologies. 

For regulatory affairs teams, this distinction is worth keeping an eye on. The immediate change is linguistic and structural, but it supports a broader regulatory environment in which alternative evidence can be considered within the same nonclinical framework.

That could become increasingly relevant as developers combine conventional toxicology with human-cell systems, organ-on-chip platforms, computational models, and other NAMs.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

The FDA’s NAM Database Adds Practical Regulatory Evidence

The terminology changes are only one part of the September announcement.

The FDA has also launched a NAM Database of Use Case Examples, providing a practical window into how these methodologies have appeared in actual FDA review materials.

The initial release contains 25 examples drawn from publicly available review documents associated with approved products.

The database is organised by methodology, allowing users to identify a NAM and then examine applications where it appeared. 

The examples span different types of approaches, including complex and two-dimensional in vitro methods, in chemico approaches ,and in silico studies.

The FDA database already identifies examples associated with products such as Symdeko and Veklury.

For industry, this changes the discussion from theoretical acceptance to documented regulatory use.

The database does not establish that a method will be accepted in another submission. The FDA explicitly states that the examples are illustrative, not exhaustive, and do not constitute guidance, approval or a recommendation for future applications.

Regulatory conclusions remain dependent on factors such as the method, endpoint, product, data package and specific application. 

That limitation is important.

Yet the database can still provide valuable intelligence for regulatory and nonclinical teams. Public review documents can show how a methodology was positioned, where it appeared in an application and what type of regulatory evidence surrounded its use.

The value is therefore contextual rather than precedential.

For companies evaluating a NAM, that context can help frame questions for regulatory discussions, identify relevant precedents in the public record and understand how alternative methods have appeared within broader evidence packages.

Image

What the FDA’s NAM Shift Means for Pharma Strategy

The immediate effect of the FDA non-animal testing policy changes is not that sponsors can simply remove animal studies from development programmes.

The more important shift is that regulatory strategy can increasingly begin with the scientific question and the evidence needed to answer it, rather than assuming the testing model in advance.

For R&D leaders, this creates several areas to watch.

Regulatory planning moves closer to method selection

A development team considering an organ-on-chip platform, human-cell model or computational approach now has a clearer regulatory vocabulary for discussing that evidence with FDA.

That does not remove the need to demonstrate scientific suitability. The FDA states that NAMs can support safety assessments when they are appropriate for the product and regulatory question. 

This makes early regulatory engagement increasingly important.

Sponsors need to establish what decision the method will inform, what biological question it addresses, how reliable the resulting data are, and how the evidence fits with the wider nonclinical package.

That approach also changes how companies should evaluate emerging platforms.

A technology should not be judged only by whether it replaces an animal experiment. Its value depends on whether it produces evidence that is relevant, reproducible, interpretable, and useful for the specific development decision.

NAMs become part of evidence architecture

The FDA’s database provides an important practical bridge between emerging science and regulatory experience.

Its 25 initial examples come from publicly available FDA review materials for approved products. Users can search by methodology and examine where the approach appeared within an FDA review document.

For regulatory teams, this creates a new intelligence resource.

A sponsor assessing a NAM can examine existing public examples before designing its own evidence strategy.

The examples do not establish acceptance for another product, but they can help teams understand how particular methods have already appeared within regulatory submissions.

This is particularly relevant as NAMs become more diverse. The FDA’s broader NAM framework includes complex in vitro systems, two-dimensional in vitro methods, in chemico approaches, and in silico models. 

The question therefore becomes less about finding a single replacement for animal testing and more about building an integrated evidence package.

Read The Looming Threat of Geopolitical Risk in Clinical Supply Chains

The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.

Image

Non-animal Testing Policy: What to Watch Next

The September rulemaking should be viewed alongside the FDA’s wider NAM programme rather than as an isolated terminology exercise.

The agency’s current NAM activities include guidance development, databases, qualification programmes, streamlined nonclinical approaches, and work on specific applications of alternative methods. 

That creates several areas for pharmaceutical leadership teams to monitor.

First, regulatory precedent will matter. As more NAM examples appear in public review materials, sponsors will have a larger evidence base from which to understand how different methodologies have been incorporated into applications.

Additionally, method qualification and scientific characterisation will remain important. The terminology change does not establish blanket acceptance for any particular technology. The FDA continues to emphasise context-specific regulatory decisions. 

Third, regulatory affairs and R&D teams will need to work more closely. NAM selection is not simply a laboratory decision. The intended regulatory use needs to be considered when the evidence strategy is designed.

Lastly, computational and human-relevant technologies will increasingly sit within the same nonclinical discussion. This includes organ-on-chip platforms, advanced cell systems, modelling approaches, and other technologies capable of generating information about human biology. 

This strongly connects with the FDA’s earlier work on alternative testing methods. Pharmatica’s Insights into the FDA’s March 2026 NAM guidance examines how sponsors can structure evidence around the intended regulatory use of a methodology and its relevance to human biology.

The September rule therefore adds another layer to an already developing framework.

Image

From Replacement Debate to Evidence Strategy

The most important change may ultimately be conceptual.

The regulatory question is becoming less binary. It is no longer simply whether an animal study was performed. Instead, sponsors increasingly need to consider which combination of evidence best answers the relevant safety question.

That does not mean animal studies disappear. The FDA has explicitly stated that the rule does not prohibit animal testing, alter evidentiary standards, or impose new requirements on sponsors. 

Instead, the NAM framework recognises that modern nonclinical development can draw from multiple scientific approaches.

This could have consequences across the development lifecycle.

Drug discovery teams may use human-relevant models earlier to investigate mechanisms and toxicity, while preclinical teams may combine NAM data with established studies to build a broader evidence package.

Regulatory teams may use the FDA’s public examples to inform discussions about proposed approaches and senior R&D leaders may also need to assess whether their organisations have the scientific, analytical, and regulatory capabilities to interpret increasingly diverse evidence.

The FDA’s terminology change does not solve those challenges. It does, however, remove a regulatory-language barrier to a more flexible evidence model.

That makes the NAM database particularly significant. The industry now has a growing public record of where these methodologies have already appeared in FDA-reviewed applications, even though each example remains context-specific.

For companies investing in next-generation nonclinical platforms, technology adoption without regulatory strategy can create expensive development risk. Regulatory strategy without appropriate scientific capability can limit the value of emerging methods.

The opportunity sits at the intersection.

Pharmatica’s previous analysis of liver-chip development illustrates this wider movement, with human-relevant models progressing through the FDA regulatory pathways rather than remaining purely experimental technologies. 

The September 2026 rules add another piece to that emerging regulatory architecture.

Modernisation Through the FDA Non-animal Testing Policy

The FDA's latest action is best understood as regulatory modernisation rather than a mandate to eliminate animal studies.

The Direct Final Rule aligns regulatory terminology with federal law and recognises a broader definition of nonclinical evidence. The companion Proposed Rule preserves a conventional rulemaking route if significant adverse comments are received.

At the same time, the NAM database provides something more practical: examples from real FDA review documents that show how alternative methodologies have already appeared in approved-product applications. 

Taken together, the policy shows that the nonclinical evidence landscape is becoming more method-diverse.

Pharma R&D teams need to understand not only which technologies exist, but also what regulatory questions each method can credibly answer, how its evidence integrates with other studies, and when FDA engagement is appropriate.

That puts scientific strategy, regulatory affairs, data interpretation, and technology assessment increasingly close together.

At Pharmatica, we track the systems, regulatory decisions, and technologies reshaping pharmaceutical development, connecting emerging evidence with the strategic context pharma leaders need to navigate change.

Pharmatica: Insight. Connection. Impact.